References
Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502–18.
Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23–4.
Goldenberg G. Treatment considerations in actinic keratosis. J Eur Acad Dermatol Venereol 2017; 31(Suppl 2): 12–6.
Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis — International League of Dermatological Societies in cooperation with the European Dermatology Forum — short version. J Eur Acad Dermatol Venereol 2015; 29: 2069–79.
Khanna R, Bakshi A, Amir Y, Goldenberg G. Patient satisfaction and reported outcomes on the management of actinic keratosis. Clin Cosmet Investig Dermatol 2017; 10: 179–84.
Kempers S, Dubois J, Forman S, et al. Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: Phase 1 and 2 results. J Drugs Dermatol 2020; 19: 1093–100.
Smolinski MP, Bu Y, Clements J, et al. Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2–391 and KX2–361). J Med Chem 2018; 61: 4704–19.
Blauvelt A, Kempers S, Lain E, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med 2021; 384: 512–20.
Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am 2019; 33: 1–12.
National Comprehensive Cancer Network (NCCN). Squamous cell skin cancer, NCCN guidelines version 1. NCCN Clinical Practice Guidelines in Oncology. NCCN, 2020. https://www.nccn.org/professionals/physician.gls/default.aspx.
Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual, 8th ed. New York: Springer International Publishing, 2017.
Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American Joint Committee on Cancer Staging Manual, 8th edition vs. the Brigham and Women’s Hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol 2019; 155: 819–25.
Scope A, Essat M, Pandor A, et al. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: a systematic review. Int J Technol Assess Health Care 2017; 33: 3245.
Kristiansen G. Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. Mod Pathol 2018; 31: S143–55.
Aaberg TM, Cook RW, Oelschlager K, Maetzold D, Rao PK, Mason JO. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol 2014; 8: 2449–60.
Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients. Skin J Cutan Med 2018; 2: 111–21.
Wysong A, Newman JG, Covinton KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol 2021; 84: 361–9.
Fox M, Brown M, Golda N, et al. Nodal staging of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol 2019; 81: 548–57.
Motley R, Arron S. Mohs micrographic surgery for cutaneous squamous cell carcinoma. Br J Dermatol 2019; 181: 233–4.
Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 2018; 78: 457–463.e2.
Harms KL, Healy MA, Nghiem P, et al. Analysis of prognostic factors from 9387 Merkell cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol 2016; 23: 3564–71.
Cornejo C, Miller CJ. Merkel cell carcinoma: Updates on staging and management. Dermatol Clin 2019; 37: 269–77.
Becker J, Eigentler T, Frerich B, et al. S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) — update 2018. J Dtsch Dermatol Ges 2019; 17: 562–76.
Vázquez-Doval J, Llombart-Cussac B, Pérez-Bustillo A, et al. Diagnosis and treatment of Merkel cell carcinoma in specialized Dermatology units: a clinical practice guideline of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2019; 110: 460–8.
National Comprehensive Cancer Network (NCCN). Merkel Cell Carcinoma NCCN Guidelines version 1. NCCN Clinical Practice Guidelines in Oncology. NCCN, 2020. https://www.nccn.org/professionals/physician.gls/default.aspx.
Jouary T, Leyral C, Doussau A, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol 2012; 23: 1074–80.
Mojica P, Smith D, Ellenhorn JDI. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 2007; 25: 1043–7.
Takagishi SR, Marx TE, Lewis C, et al. Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck. Adv Radiat Oncol 2016; 1: 244–51.
Tarabadkar ES, Fu T, Lachance K, et al. Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: analysis of 188 cases of localized disease and proposed management algorithm. J Am Acad Dermatol 2021; 84: 340–7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosures
Funding source: none. Conflicts of interest: none.
About this article
Cite this article
Rodriguez-Lomba, E., Nogueira, M., Lefevre, MA. et al. Journal Club. Eur J Dermatol 31, 424–426 (2021). https://doi.org/10.1684/ejd.2021.4069
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2021.4069